Dupixent: Frequently Asked Questions Answered
What is Dupixent?
Dupixent is the only dual inhibitor of interleukin (IL)-4 and IL-13 signalling and is approved for the treatment of atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP). It has been recently approved for children between the age of 6 and 11 years with moderate-to-severe eosinophilic asthma. The generic name of Dupixent is dupilumab. It belongs to the class of drugs called interleukin inhibitors. Dupilumab, an IL-4 receptor alpha antagonist, is a human monoclonal antibody of the immunoglobulin G4 subclass that binds to the IL-4Rα subunit and inhibits IL-4 and IL-13 signalling.
What are the uses of Dupixent?
Dupixent is used for the following conditions:
- Atopic dermatitis: Dupixent works by targeting an underlying source of inflammation that could be the main cause of uncontrolled moderate-to-severe eczema.
- Asthma: Dupixent is an add-on maintenance medication in adults and children above the age of 6 with uncontrolled moderate-to-severe eosinophilic or oral steroid-dependent asthma to improve lung function.
- Nasal polyposis: Dupixent is used with other medicines for the maintenance treatment of adults with uncontrolled CRSwNP.
The most common Side effects of Dupixent include:
- Atopic dermatitis
- Asthma
- CRSwNP